As part of an investment project supported by the Agency for the Development of the Pharmaceutical Industry, a modern pharmaceutical manufacturing facility is planned to be established within the Tashkent Pharma Park pharmaceutical cluster with the participation of Ananta Medicare.

For the implementation of the project, a land plot of 3.38 hectares has been allocated. Manufacturing processes will be organized in full compliance with the requirements of international GMP standards.

Within the framework of the project, the following production is planned:

 *sterile injectable medicines (ampoules and vials);
 *medicinal products in injectable, solid, and liquid dosage forms;
 *herbal (phytotherapeutic) products.

The socio-economic significance of the project lies in the creation of new jobs in the pharmaceutical sector, expansion of manufacturing capacity, implementation of advanced technologies, supply of the domestic market with locally produced medicines, and strengthening of the industry’s export and investment potential.

For reference:
Ananta Medicare is an international pharmaceutical company founded in 1999 in India, operating in India, the USA, the United Kingdom, Ukraine, Kazakhstan, Uzbekistan, the UAE, and the Philippines, and supplying pharmaceutical products to markets in Europe and Asia.